Autophagy Agents in Clinical Trials for Cancer Therapy: A Brief Review
Samiha Mohsen, Philip T. Sobash, Ghada Algwaiz, Noor Nasef, Safaa A. Al-Zeidaneen, Nagla Abdel Karim
Abstract
Autophagy has been of novel interest since it was first demonstrated to have effect in Burkitt's lymphoma. Since that time, the autophagy agents chloroquine and hydroxychloroquine have become the only FDA (Food and Drug Administration)-approved autophagy inhibitors. While not approved for cancer therapy, there are ongoing clinical trials to evaluate their safety and efficacy. Pevonedistat has emerged as a novel inhibitor through the neddylation pathway and is an autophagy activator. This paper summarizes and presents current clinical trials for hydroxychloroquine (HCQ), chloroquine (CQ), and Pevonedistat for the clinician.
Topics & Concepts
AutophagyHydroxychloroquineMedicineClinical trialChloroquineLymphomaFood and drug administrationCancerPharmacologyImmunologyInternal medicineBiologyMalariaDiseaseCoronavirus disease 2019 (COVID-19)Infectious disease (medical specialty)ApoptosisBiochemistryAutophagy in Disease and TherapyHistone Deacetylase Inhibitors ResearchStudies on Chitinases and Chitosanases